Investigating a rare and aggressive blood cancer called BPDCN
Targeting blastic plasmacytoid dendritic cell neoplasm (BPDCN)
This study is looking at a rare and serious blood cancer called BPDCN to find out how certain genetic changes affect the disease, with the hope of discovering new treatments that could help patients like you.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10855766 on NIH RePORTER |
What this research studies
This research focuses on blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive blood cancer that often leads to fatal outcomes within a year of diagnosis. The study aims to understand the genetic mutations that drive this disease, particularly focusing on RNA splicing factors and their role in cancer progression. By utilizing advanced DNA sequencing and genetically engineered models, researchers will explore how specific mutations contribute to the transformation of dendritic cells and identify potential treatment vulnerabilities. This approach may lead to the development of targeted therapies for patients suffering from BPDCN.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Not a fit: Patients with other types of cancers or hematologic disorders unrelated to BPDCN may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and outcomes for patients with BPDCN.
How similar studies have performed: Previous research has shown promising results in targeting genetic mutations in other cancers, suggesting potential for success in this novel approach.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Lane, Andrew a — Dana-Farber Cancer Inst
- Study coordinator: Lane, Andrew a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.